Genetic analysis of field isolates of Plasmodium falciparum has shown selective accumulation of point mutations within the immunologically sensitive sites of the circumsporozoite (CS) protein, a vaccine candidate against malaria. This raised concern whether a vaccine containing the sequence of a selected strain of P. falciparum would be able to confer protection against other variant parasites. The answer to this question remained speculative, and in this study, we have formally tested the immunological impact of such natural variations within a known cytotoxic-T-cell (CTL) epitope, which is recognized by both human and murine CTLs. With a murine model, CTLs were generated against the 7G8 strain of P. fakciparum. The ability of these CTLs to lyse histocompatible targets that were pulsed with synthetic peptides corresponding to polymorphic sequences of Brazilian, Papua New Guinean, and The Gambian isolates was determined. While these CTLs were able to recognize three of the four variant CS sequences found in Brazil and Papua New Guinea, they failed to recognize four of the five variant CS sequences found in The Gambia. Among the peptides that lost their reactivity to 7G8-specific CTL, all except one had amino acid variation in more than one residue. On the other hand, only one of the four peptides that showed a positive reaction had amino acid substitutions in more than a single residue. Thus, our findings demonstrate that natural amino acid variations in the CS protein abrogate CTL recognition. Therefore, it is important to consider the implications of these results in designing CS protein-based vaccines.
Vaccines are hoped to be an adjunct to other control and prevention strategies in combating malaria, a disease that affects nearly 300 million people annually. However, one of the major challenges in malaria vaccine development is the polymorphic nature of vaccine candidate antigens (1, 7, 9, 13) . The obvious concern is vaccine failure in a person exposed to a parasite with an antigenic variant not protected by the vaccine, thus leading to the emergence of vaccine-resistant parasites. The circumsporozoite (CS) protein is a potential vaccine antigen in the development of antimalarial vaccine. The target epitopes of the CS antigen are the central repetitive region (B epitope) and CD4+ and CD8+ cytotoxic-T-lymphocyte (CTL) determinants that map carboxyl to region II, the genusconserved region. Genetic analysis of CS genes of field parasite isolates from different regions where malaria is endemic revealed accumulation of point mutations within the regions known to harbor T-cell epitopes (3, 7, 13, 15) . We have shown that parasite isolates from areas of high endemicity exhibit greater antigenic diversity than the ones from areas of low endemicity, and it appears that some variant sequences are unique to a given geographical area (12a, 13 counts were determined by lysing with 5% Triton X-100 solution. Percent specific lysis was determined as follows: [(experimental cpm -medium control cpm)/(detergent-released cpm -medium control cpm)] x 100. The background lysis of target cells in the experiments reported in Fig. I and 2 was between 10.7 and 12.4%.
RESULTS AND DISCUSSION
The sequences of polymorphic CD8+ CTL determinant of P. falciparum CS protein as seen in the natural field population of Brazil, Papua New Guinea (PNG), and The Gambia are presented in Table 1 . As can be seen from this table, CS genes of parasite isolates from areas of high endemicity (PNG and The Gambia) showed more variation than those from areas of low endemicity (Brazil). Further, it appears that some of the amino acid substitutions are unique to parasite isolates obtained from a given geographical area. The sequence of the peptide P1 represents the CTL epitope sequence of the 7G8 strain of P. falciparum; the CS recombinant vaccinia virus and the CS gene-transfected L cells used in this study carried the 7G8 sequence (6, 8) .
The CTLs in B10.BR mice were induced by immunization with recombinant vaccinia virus containing the CS gene of P. falciparum (7G8 strain) (6) . Spleen cells from the immunized and saline-injected control mice were restimulated in vitro, and the ability of these CTLs to lyse target cells pulsed with peptides corresponding to Brazilian and PNG isolates was determined. As shown in Fig. 1 cant peptide-specific lysis (data not shown). The extent of lysis in the groups that were treated with variant peptides P2, P4, and P5 was quite similar to that of the positive control group treated with P1. All of these three variants had only single amino acid substitutions, suggesting that these variations did not affect the antigenic recognition. On the contrary, targets pulsed with peptide P3 (a sequence that had three amino acid changes) were not lysed by 7G8-specific CTLs, indicating the absence of recognition due to natural variation in this epitope.
Polymorphism in the CTL epitope was found to be more extensive in the parasite isolates obtained from The Gambia than in the ones from PNG or Brazil. The results presented in Fig. 2 demonstrate the ability of 7G8-specific CTLs to recognize the natural variants of The Gambian origin. As shown in this figure, the 7G8-specific CTLs failed to recognize four (P6, P8, P9, and PIO) of five natural variant sequences. Only peptide P7-pulsed target cells showed lysis comparable to that of the positive control group treated with P1. Our results with the epitope sequence represented by peptide PIO (representing the 3D7 clone of the NF54 strain of P. falciparumn) are inconsistent with a previous study (8) . In two separate experiments, the PIO epitope sequence consistently failed to recognize CTLs elicited against the 7G8 sequence.
Examination of the CTL immune cross-reactivity reveals that substitution of glutamic acid at position 9 a These sequences were determined by DNA sequencing of PCR-amplified genetic material isolated from field parasites (7, 13) . The geographical proportions of variants in PNG and Brazil were determined on the basis of our own published data (13) and those of others (15) . The sequences and the proportions of CS variants in The Gambia were determined on the basis of the report by Lockyer et al. (7) . Although Lockyer et al. did not find P2 and P4 sequences in The Gambian isolates, others recently (5) have found them in The Gambia. The amino acid sequence of P1 is identical to the sequence of the 7G8 strain of P. falciparum, and the CS recombinant vaccinia virus used in this study also contained the same sequence. BRA, Brazil; GAM, The Gambia.
is clear that charge substitutions of single amino acids in peptides P2, P4, and P5 are well tolerated. In the allelic variant P3, amino acid variation at positions 8 and 10, either independently or collectively, should have contributed to the loss of reactivity since change of glutamic acid to glutamine at position 5 (see p2) by itself did not affect the CTL recognition. Although changes seen in peptides P2 and P7 did not affect their cross-reactivity with the 7G8 sequence in this mouse model (H-2k background), it appears to have a deleterious effect in binding to human HLA-B35 (5). Our results with epitope P4 are in agreement with those found for humans with HLA-B35 background (5).
It is evident from this study that natural amino acid substitutions in the CS protein lead to loss of CTL recognition. This observation is consistent with similar ones in other systems (10, 11) . To function as a CTL epitope, a given peptide must meet at least two critical requirements: it should have the ability to bind major histocompatibility complex class I molecules (agretopic binding), and it should contain residues that can fit into the T-cell receptor (epitopic binding) (14) . Any change in the T-cell epitope structure that affects any one of these qualities can render it immunologically inert. At present, we do not know whether these polymorphic changes in the CTL epitope of P. falciparum CS protein affect the ability to bind to class I or T-cell receptor.
It has become evident that the optimal length of a CTL epitope may be only about 8 to 10 amino acids (5 (5, 6, 8, 12) . Despite the fact that the pattern of cross-reactivity in the CTL epitope may not be identical between human and mouse systems, we chose to do these experiments in the rodent model for the following compelling reasons: (i) most of the individuals naturally exposed to malaria show either no detectable CTL activity or very poor response against this epitope, and hence, it becomes difficult to address this question in the field settings (4, 12) ; (ii) in a region where malaria is endemic, because of multiple exposure to parasites, it is most likely that the majority of individuals are exposed to more than one antigenic type of parasite (most often, blood samples contain more than one antigenic type, indicating the widespread mixed nature of infection); (iii) unlike inbred mouse strains, humans generally express several allelic forms of class I molecules, and if in a given individual, more than one allelic form of class I molecules can present this epitope, then it will become increasingly difficult to assess the antigenic cross-reactivity; (iv) the pattern of cross-reactivity with different variant sequences may not be identical between various HLA alleles, particularly when those changes affect HLA binding; (v) although the mouse and the human are different species, both of their immune systems obey the same basic rules as far as antigen presentation and antigen recognition are concerned; and (vi) most importantly, this particular CTL epitope of the CS protein is recognized by both humans and mice. Therefore, our experiments with the mouse model helped to determine whether natural amino acid changes within this epitope can affect the antigen recognition and to provide essential background on which human studies can be developed. However, the results of this study clearly indicate that antigenic polymorphism has to be addressed in any vaccine development strategy involving CS protein.
In conclusion, we have demonstrated that natural variations in the CTL epitope of the CS protein affect antigen recognition. This finding is consistent with a previous report that showed the loss of antigenic recognition due to antigenic polymorphism within the T-helper and proliferative determinants of the CS protein (2) . Taken together, these findings strengthen the hypothesis that immune pressure has a role in the selection and maintenance of antigenic polymorphism. Thus, our results have important implications for the design of CS protein-based vaccine constructs.
